公开(公告)号：US20250059217A1

公开(公告)日：2025-02-20

申请号：US18562587

申请日：2022-05-25

Applicant: Bright Minds Biosciences Inc. ,  The Medical College of Wisconsin Inc.

Inventor： Alan Kozikowski ,  Werner Tueckmantel ,  John McCorvy ,  Uro Laban

IPC: C07F9/572 ,  A61K31/4045 ,  A61K31/5383 ,  A61K31/675 ,  C07D209/16 ,  C07D403/06 ,  C07D498/06

Abstract: This disclosure relates to heterocyclic compounds of Formula (I), Formula (II), and Formula (III) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I), Formula (II), and Formula (III) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy. Formula (I), Formula (II), Formula (III).

公开(公告)号：US20250057863A1

公开(公告)日：2025-02-20

申请号：US18940508

申请日：2024-11-07

Applicant: Insmed Incorporated

Inventor： Gina EAGLE ,  Renu GUPTA

IPC: A61K31/7036 ,  A61K9/00 ,  A61K9/127 ,  A61K31/133 ,  A61K31/407 ,  A61K31/4375 ,  A61K31/4409 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K45/06 ,  A61P31/04

Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

公开(公告)号：US20250049809A1

公开(公告)日：2025-02-13

申请号：US18787216

申请日：2024-07-29

Applicant: Board of Regents, The University of Texas System

Inventor： Fernando G. ALVAREZ ,  Pijus K. MANDAL ,  Matthew C. HORTON ,  Michael J. SOTH ,  Kang LE ,  Philip JONES ,  Timothy J. MCAFOOS ,  Priyanka SRIVASTAVA

IPC: A61K31/5383 ,  A61K45/06 ,  A61P35/02 ,  C07D498/16

Abstract: Disclosed herein are compounds, and salts thereof, which inhibit mutant IDH proteins. Also disclosed are pharmaceutical formulations and methods of treatment for diseases associated with an IDH protein having one or more neomorphic mutations, such as certain cancers.

公开(公告)号：US20250034128A1

公开(公告)日：2025-01-30

申请号：US18894069

申请日：2024-09-24

Applicant: BeiGene, Ltd.

Inventor： Ling Qin ,  Yunhang Guo ,  Zhiwei Wang

IPC: C07D417/14 ,  A61K31/429 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5383 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting Bcl-xL and treating a disease associated with the undesirable Bcl-xL activity (Bcl-xL related diseases), a method of using the compounds disclosed herein for treating tumor or cancer, and a pharmaceutical composition comprising the same.

公开(公告)号：US20250025426A1

公开(公告)日：2025-01-23

申请号：US18715394

申请日：2022-10-14

Applicant: KARLSRUHER INSTITUT FÜR TECHNOLOGIE ,  MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. ,  GEORG-AUGUST-UNIVERSITÄT STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN

Inventor： David RUDOLPH ,  Claus FELDMANN ,  Joanna NAPP ,  Frauke ALVES

IPC: A61K9/51 ,  A61K31/407 ,  A61K31/4164 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/498 ,  A61K31/5383 ,  A61K31/65 ,  A61K31/7052 ,  A61K49/00 ,  A61K51/12

Abstract: The present invention relates to nanocontainers for the synergistic transport of lipophilic and hydrophilic active ingredients or detection reagents. In particular, the nanocontainers according to the invention offer a possibility for diagnosing and/or treating diseases with combinations of active ingredients (therapy) and detection reagents (diagnostics), which have different solubility properties. The present invention further relates to a method for producing the nanocontainers according to the invention.

公开(公告)号：US20250019406A1

公开(公告)日：2025-01-16

申请号：US18889991

申请日：2024-09-19

Applicant: Immatics Biotechnologies GmbH ,  Immatics US, Inc.

Inventor： Sebastian BUNK ,  Dominik MAURER ,  Gisela SCHIMMACK ,  Heiko SCHUSTER ,  Claudia WAGNER ,  Sara YOUSEF ,  Amir ALPERT

IPC: C07K14/47 ,  A61K31/437 ,  A61K31/5383 ,  A61K35/17 ,  A61K35/76 ,  C07K14/725 ,  C12N5/0783 ,  G01N15/10 ,  G01N15/14 ,  G01N15/149 ,  G01N33/554

Abstract: The present invention relates to a method for selecting a cell or a virus expressing on its surface an antigen-binding protein specifically binding to a protein antigen of interest (PAI) while counter selection using a similar protein antigen (SPA) is applied. Further, the invention provides a method for determining the sequence of a nucleic acid encoding an antigen-binding protein or an antigen-binding part thereof and a method for producing a cell expressing a nucleic acid encoding an antigen-binding protein or an antigen-binding part thereof. The invention also relates to a method for treating a subject with a selected cell population.

公开(公告)号：US20250011334A1

公开(公告)日：2025-01-09

申请号：US18743020

申请日：2024-06-13

Applicant: Novartis AG

Inventor： Rama JAIN ,  Dennis Christofer KOESTER ,  James R. MANNING ,  Vanessa MARX ,  Daniel POON ,  James Clifford SUTTON ,  Benjamin R. TAFT ,  Lifeng WAN ,  Aregahegn YIFRU ,  Qian ZHAO

IPC: C07D487/14 ,  A61K31/5025 ,  A61K31/53 ,  A61K31/5365 ,  A61K31/5383 ,  A61K31/551 ,  A61P31/16 ,  C07D471/14 ,  C07D498/14

Abstract: The invention provides compounds of Formula (1): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.

公开(公告)号：US12178796B2

公开(公告)日：2024-12-31

申请号：US17467427

申请日：2021-09-06

Applicant: Shenzhen Guangyuan Biomaterial Co., Ltd.

Inventor： Zhichao Han ,  Shanshan Xu ,  Jia'en Wu

IPC: A61K31/337 ,  A61K31/496 ,  A61K31/513 ,  A61K31/5383 ,  A61K31/545 ,  A61K31/7068 ,  A61K47/34 ,  D01D5/00 ,  D04H1/728

Abstract: A drug-loaded nanofiber membrane includes a first fiber, a second fiber, and a drug. The drug is dispersed into the first fiber. The first fiber includes poly(lactic-co-glycolic acid) copolymer (PLGA copolymer), and the second fiber includes poly(p-dioxanone) (PDO).

公开(公告)号：US20240425486A1

公开(公告)日：2024-12-26

申请号：US18699461

申请日：2022-10-07

Applicant: Triana Biomedicines, Inc.

Inventor： William J. Greenlee ,  Nicholas Calandra ,  Soumya Ray

IPC: C07D403/12 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4365 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/517 ,  A61K31/536 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/553 ,  A61K31/554 ,  C07D209/30 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D495/04 ,  C07D498/04

Abstract: The present application discloses novel compounds, pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a compound of the disclosure. Methods of treating disease and disorders that results from abnormal activity of a target protein in a subject, are also disclosed.

公开(公告)号：US20240415861A1

公开(公告)日：2024-12-19

申请号：US18648514

申请日：2024-04-29

Applicant: Joseph Michael DeBons

Inventor： Joseph Michael DeBons

IPC: A61K31/7052 ,  A61K31/138 ,  A61K31/192 ,  A61K31/351 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/43 ,  A61K31/433 ,  A61K31/451 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/5415 ,  A61K31/573 ,  A61K31/635 ,  A61K31/7036

Abstract: Preventive prescription medication combination packs offer a proactive approach to healthcare, integrating multiple medications into a single, convenient package and its given in the start of a disease, combining medications enhances adherence by simplifying complex medication regimens, reducing pill burden, and streamlining dosing schedules. This approach is particularly advantageous for preventive care, ensuring consistent medication intake and maximizing therapeutic outcomes because its used for many diseases. Preventive combination packs improve patient convenience, reducing the need for multiple pharmacy visits and minimizing the risk of medication errors. Additionally, they facilitate better communication between patients and healthcare providers, fostering a collaborative approach to treatment.